Dr. Zhi Ven Fong emphasized multidisciplinary pancreatic cancer assessment, combining anatomy, biology, and patient fitness, with neoadjuvant therapy and advanced surgery expanding resectability.

Dr. Chris Crane highlighted ablative-dose radiation for pancreatic cancer, showing improved local control and outcomes. FOLFIRINOX remains standard, with radiation used selectively before or after surgery.

Dr. Ignacio Garrido-Laguna reviewed advances in RAS-targeted therapy for pancreatic cancer, highlighting resistance, combination strategies, next-generation RAS inhibitors, and emerging PRMT5 targets.

Dr. Lieu reviewed frontline metastatic pancreatic cancer therapy, supporting FOLFIRINOX or gemcitabine/nab-paclitaxel, with treatment tailored to patient fitness and maximizing first-line benefit.

Experts compared FOLFIRINOX and gemcitabine/nab-paclitaxel, highlighting similar efficacy, selective radiation use, emerging RAS inhibitors, and biomarker-guided combination therapies.